As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare equipment and supplies industry, including Lantheus (NASDAQ:LNTH) and its peers.

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on year to $388.2 million. Its non-GAAP profit of $1.55 per share was 18.9% above analysts’ consensus estimates.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal was unanimously approved by the Lantheus Board and is set to create a larger global player in diagnostic and therapeutic radiopharmaceuticals. The combined group is expected to integrate product portfolios and development pipelines across key imaging and oncology markets. Lantheus Holdings focuses on...

Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.

(Updates with latest market prices and developments.) US stocks climbed intraday as oil prices fe

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump

Lantheus (LNTH) has agreed to be acquired and taken private by Curium in an up to $8 billion deal th

Curium said it would pay $102.50 a share in cash for Lantheus, a 2.9% premium to Friday’s closing price of $99.64 and 8.5% above Lantheus’s closing price of $94.47 on May 21, before Bloomberg reported that Curium was circling the company.

Bloomberg reported that Curium is discussing a deal that would pay roughly $102 per Lantheus share in cash upfront plus an additional $12.50 per share in contingent value rights.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

What a fantastic six months it’s been for Lantheus. Shares of the company have skyrocketed 60.5%, hitting $105.30. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.